All articles by Catherine Eckford (European Pharmaceutical Review) – Page 58
-
NewsInnovative mass spectrometry method facilitates accurate C. auris identification
A novel high resolution mass spectrometer can accurately identify one of most common nosocomial fungal pathogens, researchers have found.
-
NewsBiopharma could reap benefits from SVB UK acquisition
One of the largest banking collapses in US history could provide the biotech sector unseen opportunities, say GlobalData.
-
NewsGSK to exclusively license novel oral antifungal
The only US Food and Drug Administration (FDA)-approved oral antifungal for vulvovaginal candidiasis will be exclusively licensed by GSK.
-
NewsNovel delivery approach demonstrates efficacy of immunotherapy
A first-in-human study showed a novel approach for delivering intrathecal and intravenous immunotherapy improved survival of melanoma patients with leptomeningeal disease (LMD).
-
News£277m investment to advance UK life sciences manufacturing
Four UK life sciences companies are set to benefit from a £277m investment in the first tranche of Life Sciences Innovative Manufacturing Fund (LSIMF) grants.
-
NewsFirst immunotherapy recommended for advanced cervical cancer
Final draft guidance published by the National Institute for Health and Care Excellence (NICE) has recommended immunotherapy pembrolizumab drug for advanced cervical cancer.
-
NewsFirst-in-class plaque psoriasis oral therapy approved in EU
Bristol Myers Squibb’s Sotyktu is the only TYK2 inhibitor approved for the treatment of any disease in the European Union.
-
NewsNew biologics manufacturing facility gets $1b investment
Eli Lilly’s new biologics manufacturing facility in Ireland will utilise technologies such as automation and support sustainable practises.
-
NewsRapid microbiology testing market growth expected 2022 to 2027
Driven partly by growth-based methods, the rapid microbiology testing market is predicted to expand considerably from 2022 to 2027, says a report.
-
NewsNasal spray for depression shows long-term efficacy
SPRAVATO® achieved significant long-term response rates in treatment-resistant depression, compared to quetiapine extended release, Janssen’s Phase IIIb study has shown.
-
NewsEMA publishes mid-point regulatory science strategy report
Progression in supporting development of precision medicine was noted as an achievement in a mid-term report on the EMA’s Regulatory Science Strategy to 2025.
-
NewsFirst mild asthma combination reliever approved in UK
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the first dual-combination, inhaled corticosteroid and long-acting beta2-agonist reliever therapy for mild asthma.
-
ArticleDeveloping novel therapies for NASH
In this exclusive interview, Dr Hank Mansbach, Chief Medical Officer of 89bio discusses clinical development of FGF21 therapy to treat fatty liver disease.
-
NewsTakeda to build £600m plasma therapy manufacturing site
Takeda’s largest manufacturing capacity expansion investment in Japan will fund the build of a new facility for plasma-derived therapies.
-
NewsFirst gene therapy recommended for AADC
NICE's final draft guidance has recommended the first and only gene therapy for children with aromatic L-amino acid decarboxylase (AADC) deficiency.
-
NewsCould Dupixent be the first biologic to treat COPD?
Dupixent® is the first biologic to demonstrate significant improvement in lung function compared to placebo, a pivotal Phase III trial has shown.
-
NewsCollaboration to produce 3D screen printed pharmaceuticals
A new collaboration between two industry players for cGMP production of 3D screen printing technologies could reduce drug development costs.
-
NewsIdentifying origin of fungi in cleanrooms
Microbiology expert Tim Sandle’s recent video examined identifying the origin of fungi in pharmaceutical cleanrooms.
-
NewsCPHI Pharma Awards marks 20th anniversary
Three new categories added to the CPHI Pharma Awards mark its 20th anniversary edition and celebrates innovation in the industry.
-
NewsKite releases pivotal CAR T therapy Phase III study results
Yescarta® is the first treatment in over 30 years to show statistically significant improvement in overall survival in R/R large B-cell lymphoma versus historical SOC.